ArticleThe Journal of infectious diseases2015
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.
Article in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 52 citations in OpenAlex.
- Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19.Drug development research · 2022Trial
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Human Microbiota-Associated Pig Models for Translational Microbiome Research: A Scoping Review.International journal of molecular sciences · 2026Article
- Recent advances in fecal microbiota transplantation forFrontiers in microbiomes · 2024Review
- Colostrum Quality in Different Goat Breeds Reared in Northern Italy.Animals : an open access journal from MDPI · 2023Article
- Article
- Bovine colostrum and its potential contributions for treatment and prevention of COVID-19.Frontiers in immunology · 2023Review
- Development of spirulina for the manufacture and oral delivery of protein therapeutics.Nature biotechnology · 2022Article
- Hyper-Immune Bovine Milk as an Immunological and Nutritional Supplement for COVID-19.Frontiers in nutrition · 2022Article
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents.PloS one · 2022Article
- Translational Aspects of the Immunology of Clostridioides difficile Infection: Implications for Pediatric Populations.Journal of the Pediatric Infectious Diseases Society · 2021Review
- Frontiers in antibiotic alternatives forWorld journal of gastroenterology · 2021Article
- A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- A Narrative Review on the Unexplored Potential of Colostrum as a Preventative Treatment and Therapy for Diarrhea in Neonatal Dairy Calves.Animals : an open access journal from MDPI · 2021Review
- Alteration of Intestinal Microbiome ofAntibiotics (Basel, Switzerland) · 2021Article
- A pilot study of an anti-endotoxin Ig-enriched bovine colostrum to prevent experimental sepsis.Innate immunity · 2021Article
- Breast Milk: A Source of Functional Compounds with Potential Application in Nutrition and Therapy.Nutrients · 2021Review
- Anti-virulence strategies forGut microbes · 2020Review
- A Novel, Orally Delivered Antibody Therapy and Its Potential to PreventFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundClostridium difficile is a primary cause of antibiotic-associated diarrhea that typically develops when gut microbiota is altered. Conventional treatment for C. difficile infection (CDI) is additional antimicrobial administration, which further disrupts normal intestinal microbiota, often resulting in poor treatment outcomes.
methodsA pregnant dairy cow was repeatedly immunized with recombinant mutants of toxins A and B produced by C. difficile, and the resultant hyperimmune bovine colostrum (HBC) was evaluated for therapeutic efficacy in gnotobiotic piglets with diarrhea due to CDI. Control piglets received nonimmune colostrum. To determine the impact of HBC on gut microbiota, 1 of 2 groups of piglets transplanted with normal human gut microbiota was treated with HBC.
resultsNonimmune colostrum-treated piglets developed moderate to severe diarrhea and colitis. In contrast, HBC-treated piglets had mild or no diarrhea and mild or no colitis. Lyophilization had no detectable impact on HBC efficacy. HBC had no discernible effect on the composition of normal human gut microbiota in the porcine intestinal tract.
conclusionsHBC provides an oral, cost-effective, and safe alternative to antibiotic therapy for CDI. By preserving intestinal microbiota, HBC may be more efficacious than antibiotics. Additional studies are warranted to establish HBC as a viable immunotherapeutic agent for human use against CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.